The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | The rationale behind targeting ROR1 in CLL and MCL
Parag Jasani, MBBS, MRCP, FRCPath, FRCP, University College Hospital, London, UK, talks on the rationale behind the first-in-human Phase I study (NCT04763083) investigating a bispecific T-cell engager, NVG-111, which targets CD3 and ROR1, in patients with relapse-refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). ROR1 is expressed in both hematological and solid cancers and is not usually expressed on normal tissue, thereby significantly reducing the risk of off-target side effects. Many solid and hematological cancers possess cancer-initiating stem cells on which ROR1 is expressed, thus, targeting ROR1 may hold the potential of broadening its use to multiple malignancies. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
